Gennadiy D. Telegeev

Gennadiy D. Telegeev

Institute of Molecular Biology and Genetics, Kyiv, Kyyiv, Misto, Ukraine
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in OncoTargets and Therapy
Verified
Journal Article
Open access
Anna DubrovskaAnna Dubrovska
Anna Dubrovska
MCMonica Cojoc
Monica Cojoc
CPClaudia Peitzsch
Claudia Peitzsch
FTFranziska Trautmann
Franziska Trautmann
LPLeo Polishchuk
Leo Polishchuk
GTGennadiy D. Telegeev
Gennadiy D. Telegeev
Peer reviewed article authored by (Cojoc M, Peitzsch C, Trautmann F, Polishchuk L, Telegeev GD, Dubrovska A). Read article or submit your manuscript for publishing.

5 October 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ASAladdin Y. Shchaslyvyi
Aladdin Y. Shchaslyvyi
SASvitlana V. V Antonenko
Svitlana V. V Antonenko
MTMaksym G. Tesliuk
Maksym G. Tesliuk
GTGennadiy D. Telegeev
Gennadiy D. Telegeev
In the realm of gene therapy, a pivotal moment arrived with Paul Berg’s groundbreaking identification of the first recombinant DNA in 1972. This achievement set the stage for future breakthroughs. Conditions once considered undefeatable, like melanoma, pancreatic cancer, and a host of other ailments, are now being addressed at their root cause—the genetic level. Presently, the gene therapy landscape stands adorned with 22 approved in vivo and ex vivo products, including IMLYGIC, LUXTURNA, Zolgensma, Spinraza, Patisiran, and many more. In this comprehensive exploration, we delve into a rich assortment of 16 drugs, from siRNA, miRNA, and CRISPR/Cas9 to DNA aptamers and TRAIL/APO2L, as well as 46 carriers, from AAV, AdV, LNPs, and exosomes to naked mRNA, sonoporation, and magnetofection. The article also discusses the advantages and disadvantages of each product and vector type, as well as the current challenges faced in the practical use of gene therapy and its future potential.

ASAladdin Y. Shchaslyvyi
Aladdin Y. Shchaslyvyi
SASvitlana V. V Antonenko
Svitlana V. V Antonenko
GTGennadiy D. Telegeev
Gennadiy D. Telegeev
The connection between chronic psychological stress and the onset of various diseases, including diabetes, HIV, cancer, and cardiovascular conditions, is well documented. This review synthesizes current research on the neurological, immune, hormonal, and genetic pathways through which stress influences disease progression, affecting multiple body systems: nervous, immune, cardiovascular, respiratory, reproductive, musculoskeletal, and integumentary. Central to this review is an evaluation of 16 Behavioral Stress Reduction Programs (BSRPs) across over 200 studies, assessing their effectiveness in mitigating stress-related health outcomes. While our findings suggest that BSRPs have the potential to enhance the effectiveness of medical therapies and reverse disease progression, the variability in study designs, sample sizes, and methodologies raises questions about the generalizability and robustness of these results. Future research should focus on long-term, large-scale studies with rigorous methodologies to validate the effectiveness of BSRPs.

25 November 2024 in Cytology and Genetics
Verified
Journal Article
Closed access
PDF file
SDSvitlana Dybkova
Svitlana Dybkova
OLOlha Borisivna Liutko
Olha Borisivna Liutko
MDMykhaylo Dybkov
Mykhaylo Dybkov
KVKateryna Vitrak
Kateryna Vitrak
LRLiudmyla Rieznichenko
Liudmyla Rieznichenko
GTGennadiy D. Telegeev
Gennadiy D. Telegeev
The use of tetracyclines in medicine, veterinary medicine, and stock raising has led to the spread of bacterial resistance to tetracycline, particularly am

14 November 2017
Verified
Book Chapter
Closed access
PDF file
PTP. Telegeeva
P. Telegeeva
NKNataliya V. Kutsevol
Nataliya V. Kutsevol
SFS. Filipchenko
S. Filipchenko
GTGennadiy D. Telegeev
Gennadiy D. Telegeev
Drug targeting to specific organs and tissues is one of the crucial endeavors of modern pharmacotherapy. Controlled targeting at the site of action and reduced time of exposure of non-targeted tissues increase the efficacy of the treatment and reduce toxicity and side effects, improving compliance and convenience. Nanocarriers based on the branched copolymers dextran- graft-polyacrylamide were synthesized and characterized and were tested on phagocytic cells. It was shown that these nanoparticles are actively captured by phagocytic cells, and that they are not cytotoxic (90% ± 2% live cells at 0.01 mkg/ml). The polymer nanoparticles loaded with cisplatinum at different concentrations from 0.01 to 0.1 mkd/ml yielded a percentage of living cells between 28% and 76%. Taking into account that our nanoparticles will act mainly on malignant phagocytic cells and do not affect healthy cells, they can thus potentially be used for the therapeutic treatment of tumor cells having phagocytic activity.

25 September 2024 in Faktori eksperimental'noi evolucii organizmiv
Verified
Journal Article
Open access
PDF file
DND. O. Nishchenko
D. O. Nishchenko
SAS. V. Antonenko
S. V. Antonenko
DGD. S. Gurianov
D. S. Gurianov
GTGennadiy D. Telegeev
Gennadiy D. Telegeev
Aim. Malignant neoplasms pose a significant challenge in medicine, requiring a deep understanding of the molecular mechanisms underlying their pathogenesis. This study aimed to investigate the expression profile and subcellular localization of ubiquitin-specific protease 1 (USP1) in various types of cancer. Methods. Using the TCGA database, an analysis of USP1 expression was conducted across different cancer types. Immunofluorescence analysis with confocal microscopy was utilized to determine the subcellular localization of USP1 in chronic myeloid leukemia (CML) and prostate cancer cells. Results. Bioinformatic analysis revealed heterogeneous USP1 expression, with increased levels observed in acute myeloid leukemia, esophageal carcinoma, and glioblastoma multiforme. Immunofluorescence analysis confirmed nuclear localization of USP1 in CML cells and showed that inhibiting USP1 interaction with UAF1 using ML323 disrupts its transport to the nucleus. Prostate cancer cells exhibited both nuclear and atypical cytoplasmic USP1 localization, suggesting alterations in its expression, interaction with UAF1, and disruption of signaling pathways. Conclusions. USP1 plays a multifaceted role in cancer processes, with dysregulation of its expression and localization associated with tumorigenesis. Targeting USP1 holds therapeutic potential for cancer treatment.